Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Plain-language summary
This trial is testing CD5-directed CAR-T cell therapy for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Lymphoma came back or did not respond to prior treatment
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Autologous CD5.CAR/28zeta CAR T cells (GENETIC): Three dose levels will be evaluated: Dose level one: 1×10\^7 cells/m2 Dose level two: 5×10\^7 cells/m2 Dose level three: 1×10\^8 cells/m2 | Allogeneic CD5.CAR/28zeta CAR T cells (GENETIC): Three dose levels will be evaluated: Dose level one: 1×10\^7 cells/m2 Dose level two: 5×10\^7 cells/m2 Dose level three: 1×10\^8 cells/m2
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details